![Steven Libutti: Trusting science as COVID's new wave looms over New Jersey](https://cdn.cancerletter.com/media/2020/11/25181146/TCL46-42-storm_4x3.jpg)
![Steven Libutti: Trusting science as COVID's new wave looms over New Jersey](https://cdn.cancerletter.com/media/2020/11/25181146/TCL46-42-storm_4x3.jpg)
Cover Story
Conversation with The Cancer LetterCOVID-19 & CancerFree
As he watches COVID-19 numbers climb in New Jersey, Steven K. Libutti reviews all the things he had learned last spring, when the pandemic first slammed the state.
In Brief
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for Nov. 2020
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions” - Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills